SCHEMBL797946

SCHEMBL797946

CC(C)=CCCC(C)=CC(O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
TRPV1 Q8NER1 2/20 0.43
PGR P06401 1/20 0.43
HTR1A P08908 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
PTGS1 P23219 1/20 0.43
PDE4A P27815 1/20 0.43
MAPK1 P28482 1/20 0.43
DRD3 P35462 1/20 0.43
SNCA P37840 1/20 0.43
PDE3A Q14432 1/20 0.43
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
KMT2A Q03164 3/20 0.42
CYP3A4 P08684 4/20 0.42
TRPA1 O75762 2/20 0.42
LMNA P02545 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
HIF1A Q16665 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL797945 1.00 MAPT (0.43) MAPTTRPV1PGRHTR1AADORA3
SCHEMBL17844421 0.85 TRPV1 (0.47) MAPTTRPV1PGRHTR1AADORA3
SCHEMBL22042233 0.83 TRPV1 (0.43) MAPTTRPV1PGRHTR1AADORA3
SCHEMBL795008 0.82 MAPT (0.42) MAPTTRPV1PGRHTR1AADORA3
SCHEMBL22445229 0.82 TRPA1 (0.44) MAPTTRPV1PGRHTR1AADORA3
SCHEMBL795007 0.82 MAPT (0.42) MAPTTRPV1PGRHTR1AADORA3
SCHEMBL15303011 0.79 TRPV1 (0.48) MAPTTRPV1PGRHTR1AADORA3
SCHEMBL794719 0.79 TRPV1 (0.48) MAPTTRPV1PGRHTR1AADORA3
SCHEMBL1962023 0.78 PPARG (0.42) MAPTTRPV1ADORA3MAPK1DRD3
SCHEMBL12730003 0.76 ICMT (0.48) MAPTTRPV1PGRHTR1AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130267571-A1 TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS NEUROQUEST INC. (CA) 2013-10-10 US disclosed
EP-2616056-A1 TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS Neuroquest Inc. (CA) 2013-07-24 EP disclosed
WO-2012034232-A1 TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS NEUROQUEST INC. (CA) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267571-A1 TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS PMP22, PTGES, GGPS1 MAPT 1379/4885TRPV1 8/4885PGR 2632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.